Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCT (DXACT)
Prospective Imaging-based Assessment of Skeletal Deterioration After Kidney Transplantation Using DXA and HR-pQCT (DXACT Study)
The goal of this observational study is to learn how bone health changes during the first year after kidney transplantation in adults receiving their first kidney transplant.
The main questions it aims to answer are:
- How many patients show a clinically relevant decline in bone density or bone structure within 12 months after transplantation?
- Does a standard bone density scan (DXA) detect these changes as well as a high-resolution scan of bone structure (HR-pQCT)?
Participants will:
- Have a DXA scan of the lower spine, hip and forearm and an HR-pQCT scan of the forearm and lower leg shortly after transplantation and again after 12 months. Participants followed up in Innsbruck may also have these scans after 6 months.
- Give blood and urine samples at the same visits, taken together with routine blood tests whenever possible, for bone and mineral markers and storage in a biobank.
The study does not change any treatment. All treatment decisions remain with the patients' physicians.
研究概览
地位
详细说明
Bone mineral density declines rapidly during the first 6-12 months after kidney transplantation, driven by glucocorticoid exposure, persistent chronic kidney disease-mineral and bone disorder (CKD-MBD) and changes in bone turnover. This period coincides with the highest fracture risk. DXA-scans provide areal bone mineral density only and cannot distinguish cortical from trabecular bone or assess microarchitecture, so it may underestimate early cortical deterioration. HR-pQCT measures volumetric bone mineral density, cortical and trabecular microarchitecture and, by finite element analysis, estimated bone strength.
DXACT is an investigator-initiated, prospective, single-centre observational cohort study at the Medical University of Innsbruck. Baseline clinical and laboratory assessment is performed 7 +/- 2 days and imaging 10 +/- 7 days after transplantation; assessments are repeated at 12 months, with an optional 6-month visit for participants followed locally. HR-pQCT is performed at the distal radius and distal tibia of the dominant side (contralateral side if a vascular access or implant is present); DXA at the lumbar spine (L1-L4), hip and distal radius (33%).
Clinically relevant skeletal deterioration is defined as a change exceeding the least significant change (LSC = 2.77 x precision CV) of the respective modality and parameter. Laboratory assessments include parathyroid hormone, 25-hydroxy- and 1,25-dihydroxyvitamin D, calcium, phosphate, P1NP, bone-specific alkaline phosphatase, TRAP5b, CTX, osteocalcin and osteoprotegerin. EDTA plasma and urine are stored in a pseudonymised biobank at -80 °C.
Analyses are primarily descriptive and exploratory. Planned analyses include agreement and discordance between DXA- and HR-pQCT-based classification, associations of imaging changes with biochemical markers and clinical factors (age, sex, dialysis vintage, cumulative glucocorticoid dose, rejection, graft function), and comparison by graft function at 12 months. Incident fragility fractures beyond 12 months may be retrieved from routine clinical records without further participant contact.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Clemens Untersulzner, MD
- 电话号码:+43 50504 84848
- 邮箱:clemens.untersulzner@i-med.ac.at
研究联系人备份
- 姓名:Andreas Kronbichler, MD, PhD
- 电话号码:+43 50504 25855
- 邮箱:andreas.kronbichler@i-med.ac.at
学习地点
-
-
Tyrol
-
Innsbruck、Tyrol、奥地利、6020
- 招聘中
- Medical University of Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension
-
接触:
- Clemens Untersulzner, MD
- 电话号码:+43 50504 84848
- 邮箱:clemens.untersulzner@i-med.ac.at
-
接触:
- Andreas Kronbichler, MD, PhD
- 电话号码:+43 50504 25855
- 邮箱:andreas.kronbichler@i-med.ac.at
-
首席研究员:
- Andreas Kronbichler, MD, PhD
-
副研究员:
- Clemens Untersulzner, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult recipients of a first kidney transplant (living or deceased donor) treated at the Medical University of Innsbruck, Austria, who are approached by the study team within 10 days after transplantation.
描述
Inclusion Criteria:
- Age 18 years or older at the time of kidney transplantation
- First kidney transplantation (living or deceased donor)
- Ability and willingness to provide written informed consent
- Enrolment possible within 10 days after kidney transplantation
- Clinical stability sufficient to undergo imaging procedures
Exclusion Criteria:
- Previous kidney transplantation
- Prior or ongoing treatment with antiresorptive or osteoanabolic therapies (e.g. bisphosphonates, denosumab, teriparatide) at the time of transplantation
- Conditions precluding reliable bone imaging, including metal implants at the measurement sites
- Contraindications to HR-pQCT or DXA
- Inability to undergo imaging due to physical or technical limitations
- Known metabolic bone diseases unrelated to chronic kidney disease-mineral and bone disorder (CKD-MBD)
- Any condition that, in the opinion of the investigator, would interfere with study participation, data quality or protocol adherence
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Kidney transplant recipients
Adults (18 years or older) who received a first kidney transplant (living or deceased donor) at the Medical University of Innsbruck and are enrolled within 10 days after transplantation. |
Dual-energy X-ray absorptiometry of the lumbar spine (L1-L4), hip and distal radius (33%) and high-resolution peripheral quantitative computed tomography of the distal radius and distal tibia, performed at baseline (10 +/- 7 days after kidney transplantation) and at 12 months, with an optional 6-month visit. Imaging is used for research only; no treatment is assigned.
其他名称:
Blood and urine samples at each study visit, taken together with routine blood draws, for markers of bone and mineral metabolism and storage in a biobank. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants With Clinically Relevant Skeletal Deterioration on HR-pQCT
大体时间:Baseline (10 +/- 7 days after transplantation) to 12 months
|
Deterioration exceeding the least significant change (LSC = 2.77 x precision CV) in at least one of cortical thickness, cortical porosity or finite element-derived failure load at the distal radius or distal tibia. |
Baseline (10 +/- 7 days after transplantation) to 12 months
|
|
Proportion of Participants With Clinically Relevant Skeletal Deterioration on DXA
大体时间:Baseline (10 +/- 7 days after transplantation) to 12 months
|
Decrease in areal bone mineral density exceeding the site-specific least significant change at the lumbar spine (L1-L4), hip or distal radius (33%). |
Baseline (10 +/- 7 days after transplantation) to 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Cortical Thickness
大体时间:Baseline to 12 months
|
Absolute (mm) and relative (%) change in cortical thickness at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Cortical Porosity
大体时间:Baseline to 12 months
|
Absolute (percentage points) and relative change in cortical porosity at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Total Volumetric BMD
大体时间:Baseline to 12 months
|
Absolute (mg HA/cm³) and relative (%) change in total volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Cortical Volumetric BMD
大体时间:Baseline to 12 months
|
Absolute (mg HA/cm³) and relative (%) change in cortical volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Trabecular Volumetric BMD
大体时间:Baseline to 12 months
|
Absolute (mg HA/cm³) and relative (%) change in trabecular volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Trabecular Number
大体时间:Baseline to 12 months
|
Absolute (1/mm) and relative (%) change in trabecular number at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Trabecular Thickness
大体时间:Baseline to 12 months
|
Absolute (mm) and relative (%) change in trabecular thickness at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Trabecular Separation
大体时间:Baseline to 12 months
|
Absolute (mm) and relative (%) change in trabecular separation at the distal radius and distal tibia measured by HR-pQCT. |
Baseline to 12 months
|
|
Change in Biochemical Markers of Bone and Mineral Metabolism
大体时间:Baseline to 12 months
|
Change in parathyroid hormone, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcium, phosphate, P1NP, bone-specific alkaline phosphatase, TRAP5b, CTX, osteocalcin and osteoprotegerin |
Baseline to 12 months
|
|
Change in Estimated Bone Strength (Failure Load)
大体时间:Baseline to 12 months
|
Absolute and relative change in finite element-derived failure load (N) at the distal radius and distal tibia. |
Baseline to 12 months
|
|
Change in Areal Bone Mineral Density
大体时间:Baseline to 12 months
|
Absolute and relative change in areal BMD (g/cm2) at the lumbar spine (L1-L4), total hip, femoral neck and distal radius (33%) measured by DXA. |
Baseline to 12 months
|
|
Skeletal Changes by Graft Function
大体时间:12 months
|
Comparison of HR-pQCT and DXA changes between participants with eGFR >= 60 and < 60 mL/min/1.73 m2 (CKD-EPI 2021) at 12 months. |
12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Discordance Between DXA and HR-pQCT Classification
大体时间:12 months
|
Proportion of participants classified differently by DXA and HR-pQCT, in particular stable DXA with deterioration on HR-pQCT. |
12 months
|
|
Association of Dialysis Vintage With Skeletal Deterioration
大体时间:Baseline to 12 months
|
Pre-transplant dialysis duration (continuous; pre-emptive, < 12, >= 12 months) as predictor of imaging-derived skeletal changes. |
Baseline to 12 months
|
|
Incident Fragility Fractures
大体时间:Up to 5 years after transplantation
|
Fragility fractures retrieved from routine clinical records without participant contact. |
Up to 5 years after transplantation
|
合作者和调查者
调查人员
- 首席研究员:Andreas Kronbichler, MD, PhD、Medical University Innsbruck
出版物和有用的链接
一般刊物
- Jorgensen HS, Behets G, Bammens B, Claes K, Meijers B, Naesens M, Sprangers B, Kuypers DRJ, Cavalier E, D'Haese P, Evenepoel P. Natural History of Bone Disease following Kidney Transplantation. J Am Soc Nephrol. 2022 Mar;33(3):638-652. doi: 10.1681/ASN.2021081081. Epub 2022 Jan 19.
- Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019 Jun;95(6):1461-1470. doi: 10.1016/j.kint.2018.12.024. Epub 2019 Mar 4.
- Untersulzner C, Pirklbauer M, Evenepoel P, Zoller H, Kronbichler A. Bone Mineral Density Loss After Kidney Transplantation: Metabolic Determinants, Diagnostic Approaches, and Preventive Strategies. Kidney Int Rep. 2026 Jun 30;11(9):106685. doi: 10.1016/j.ekir.2026.106685. eCollection 2026 Sep.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- DXACT-003
- 1140/2026 (其他标识符:Ethics Committee of the Medical University of Innsbruck)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared publicly, as participant consent does not cover transfer to third parties. De-identified data may be made available by the study lead upon reasonable request, subject to approval by the ethics committee and data protection regulations.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.